Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Selenium in Graves Hyperthyroidism and Orbitopathy
source: Ophthalmic Plastic and Reconstructive Surgery
year: 2018
authors: Marinò M, Menconi F, Rotondo Dottore G, Leo M, Marcocci C
summary/abstract:Purpose:
To review the in vitro and in vivo studies supporting a role of selenium for the treatment of mild Graves orbitopathy.
Methods:
Review of the current literature on the role of selenium in the management of Graves orbitopathy.
Results:
Graves orbitopathy (GO) is a disfiguring and disabling disorder usually observed in patients with Graves hyperthyroidism, and more rarely in patients with hypothyroid autoimmune thyroiditis or in the absence of overt thyroid dysfunction. Noninvasive treatments include intravenous glucocorticoids and orbital radiotherapy and are generally offered to patients with moderately severe GO. In contrast, patients with mild GO are generally treated only with local measures. Thus, the benefits of intravenous glucocorticoids in mild GO are limited and do not justify the risks that the treatment carries. However, a medical treatment for mild GO is heavily wanted, as a relevant proportion of patients have a significant decrease in their quality of life, and GO can progress into more severe forms. Because of the role of oxidative stress in the pathogenesis of GO, an antioxidant approach has been proposed and the antioxidant agent selenium has been shown to be effective for GO.
Conclusion:
Studies have shown that a 6-month course of sodium selenite can improve the course of mild GO and prevent deterioration when compared with placebo.
DOI: 10.1097/IOP.0000000000001136
read more
Related Content
-
Quality of Life and Neuropsychiatric Disorders in Patients With Graves’ Orbitopathy: Current ConceptsGraves' disease (GD) is an autoimmune ch...
-
Michael K. Yoon, MDDr. Michael Yoon is a member of the Mass...
-
Julia: Hindsight and knowledge are wonderful thingsI am waking up from a nightmare and the ...
-
Comparison of Two Different Regimens of Intravenous Methylprednisolone for Patients With Moderate to Severe and Acti...The intravenous methylprednisolone (iv M...
-
Graves’ Eye Disease FAQWhat is the Thyroid Gland? The thyroid ...
-
Horizon Therapeutics plc Reports Strong Third-Quarter 2019 ResultsHorizon Therapeutics plc today announced...
-
The Effect of Short-Term Treatment With Lithium Carbonate on the Outcome of Radioiodine Therapy in Patients With Lon...Objective: The outcome of radioiodine t...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
myBinder